Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.

The Journal of biological chemistry - 11 Nov 2011

Sharma Vandana, Ichikawa Mie, He Ping, Scott David A, Bravo Yalda, Dahl Russell, Ng Bobby G, Cosford Nicholas D P, Freeze Hudson H

Abstract excerpt

Congenital disorders of glycosylation (CDG) are rare genetic disorders due to impaired glycosylation. The patients with subtypes CDG-Ia and CDG-Ib have mutations in the genes encoding phosphomannomutase 2 (PMM2) and phosphomannose isomerase (MPI or PMI), respectively. PMM2 (mannose 6-phosphate →...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Disorders of Glycosylation
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibroblasts

Share to Glycosylation

Share to HeLa Cells

Share to Mannose

Share to Phosphotransferases (Phosphomutases)

Share to Zebrafish

Source

Open in PubMed Open full text

Identifiers

PMID: 21949237
DOI: 10.1074/jbc.M111.285502
PMCID: PMC3234766

Genes

MPI
PMM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21949237-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phosphomannose isomerase inhibitors improve N-glycosylation in selected phosphomannomutase-deficient fibroblasts.PMID 21949237Read ↗

A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementation.Semantic proximity Read ↗

Ablation of mouse phosphomannose isomerase (Mpi) causes mannose 6-phosphate accumulation, toxicity, and embryonic lethality.Semantic proximity Read ↗

O-GlcNAcylation modulates expression and abundance of N-glycosylation machinery in an inherited glycosylation disorder.Semantic proximity Read ↗

[Advances in the diagnosis and treatment of phosphomannomutase 2 deficiency].Semantic proximity Read ↗

N-glycosylation deficiency reduces ICAM-1 induction and impairs inflammatory response.Semantic proximity Read ↗

A hypomorphic Mpi mutation unlocks an in vivo tool for studying global N-glycosylation deficiency.Semantic proximity Read ↗

A genome-wide CRISPR screen identifies the glycosylation enzyme DPM1 as a modifier of DPAGT1 deficiency and ER stressSemantic proximity Read ↗

In vitro treatment with liposome-encapsulated Mannose-1-phosphate restores N-glycosylation in PMM2-CDG patient-derived fibroblasts.Semantic proximity Read ↗

Metabolic manipulation of glycosylation disorders in humans and animal models.Semantic proximity Read ↗

Targeted disruption of the mouse phosphomannomutase 2 gene causes early embryonic lethality.Semantic proximity Read ↗

Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes.Semantic proximity Read ↗

Hydrophobic Man-1-P derivatives correct abnormal glycosylation in Type I congenital disorder of glycosylation fibroblasts.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.